Anti-Coagulants - Estonia

Estonia

The Anti-Coagulants market in Estonia is expected to achieve a revenue of US$8.00m by 2024.
The market is anticipated to experience a consistent annual growth rate (CAGR 2024-2029) of 7.64%, leading to a market volume of US$11.56m by 2029.
When compared on a global scale, United States is projected to generate the highest revenue of US$16,740.00m in 2024.
In Estonia, the demand for oral anticoagulants has been steadily increasing, driven by an aging population and a rising prevalence of cardiovascular diseases.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Estonia has been experiencing growth in recent years due to various factors.

Customer preferences: Patients in Estonia are increasingly seeking out Anti-Coagulants as a preventative measure against blood clots and strokes. This is due to the rising awareness of the benefits of these drugs and the growing elderly population in the country. Additionally, patients are increasingly opting for newer, more effective Anti-Coagulants over traditional options.

Trends in the market: One trend in the Anti-Coagulants market in Estonia is the increasing use of direct oral Anti-Coagulants (DOACs) over traditional options such as warfarin. DOACs are more effective and easier to use, as they do not require regular blood tests and dietary restrictions. As a result, they are becoming the preferred choice for doctors and patients alike.Another trend in the market is the increasing use of Anti-Coagulants for off-label purposes, such as preventing recurrent miscarriages. This is driving demand for these drugs and contributing to the overall growth of the market.

Local special circumstances: Estonia has a small population and a relatively low incidence of cardiovascular disease compared to other European countries. However, the country has a growing elderly population, which is driving demand for Anti-Coagulants as a preventative measure against stroke and other age-related health issues.

Underlying macroeconomic factors: Estonia has a stable economy and a well-developed healthcare system, which is contributing to the growth of the Anti-Coagulants market. Additionally, the country has a high level of healthcare expenditure per capita, which is enabling patients to access the latest and most effective treatments.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.